Novartis OTC Facility Improves Regulatory Report Card
This article was originally published in The Tan Sheet
Executive Summary
CEO Joe Jimenez says FDA officials did not make form 483 observations following a week-long inspection of the firm’s Lincoln, Neb., plant. Consumer product sales increased 11% in the third quarter as Novartis returned some recalled OTC brands to U.S. stores.